biostudies-literatureRocco GFiona and Stanley Druckenmiller Center for Lung Cancer ResearchNational Cancer InstituteNCI NIH HHSNational Institutes of Health1272-1283https://www.ebi.ac.uk/biostudies/studies/S-EPMC11380592biostudies-literatureUnknown19(9)<h4>Introduction</h4>Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer.<h4>Methods</h4>This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2-0.7]; high-risk, [≥Journal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology.PMC11380592P30 CA008748Vanstraelen SKelly SPennazza GHuang JAdusumilli PSGrasso STan KSCrucitti PMolena DBains MSCorba RJJones DRRusch VWWeiss HZompanti ASantonico MGinsberg MSIncalzi RABott MJPark BJFinamore PMerone MSihag SGray KRocco GDowney RJCirelli MVoli CMcKnight ALongo FIsbell JMVincent ASolomon SBfalseA Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology.<h4>Introduction</h4>Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer.<h4>Methods</h4>This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2-0.7]; high-risk, [≥2024-01-01T00:00:00Z2024 Sep2026-05-29T07:01:45.496Z2026-04-08T03:52:06.895ZS-EPMC113805923876212010.1016/j.jtho.2024.05.006